Vimarsana
Biggest News Aggregation in the World

Page 40 - Multiple System Atrophy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Multiple System Atrophy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Multiple System Atrophy Today - Breaking & Trending Today

Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders - Vimarsana News

Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders

Published: September 8, 2022

/PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor...

Source: prnewswire.com
Related Topics:
United StatesMiltonh WernerAlex LoboMilton WernerMovement DisordersInhibikase Therapeutics IncCompany ContactConference CenterInternational CongressPrnewswire Inhibikase Therapeutics IncMadrid Marriott Auditorium HotelSternir IncAbelson Tyrosine KinasesChief Executive OfficerFrance GalleryAbelson Tyrosine KinaseAbleson TyrosineMultiple System AtrophyPrivate Securities Litigation Reform ActInhibikase TherapeuticsHealth Care Amp Hospitals Medical Pharmaceuticals Trade Show News
Inhibikase Therapeutics Appoints Gisele Dion to Board of Directors - Vimarsana News

Inhibikase Therapeutics Appoints Gisele Dion to Board of Directors

Published: September 1, 2022

/PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course...

Source: prnewswire.com
Related Topics:
United StatesMiltonh WernerGisele DionAlex LoboElizabeth OfarrellAmerica PhCytek BiosciencesCompany Board Of DirectorsInhibikase Therapeutics IncCompany ContactShire PharmaceuticalsCompensation CommitteeFairfield UniversityAudit CommitteeTakeda PharmaceuticalsSternir IncInhibikase TherapeuticsElizabetho FarrellChief ExecutiveAudit Advisor Group MemberPharmaceutical ResearchSenior Vice PresidentChief Accounting OfficerCorporate ControllerManagement Information Systems
Inhibikase Therapeutics Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia - Vimarsana News

Inhibikase Therapeutics Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia

Published: August 26, 2022

/PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor...

Source: prnewswire.com
Related Topics:
United StatesMiltonh WernerAlex LoboInhibikase Therapeutics IncCompany ContactDrug AdministrationPrnewswire Inhibikase Therapeutics IncSternir IncAbelson Tyrosine KinasesInvestigational New DrugChronic Myelogenous LeukemiaStudy May ProccedAbelson Tyrosine KinaseOrphan Drug DesignationChief ExecutiveAbleson TyrosineMultiple System AtrophyPrivate Securities Litigation Reform ActInhibikase Therapeutics
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe - Vimarsana News

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe

Published: August 25, 2022

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
Related Topics:
United KingdomUnited StatesSan FranciscoDavid StamlerCompany PhaseNational Institute Of HealthEuropean CommissionAlterity TherapeuticsMultiple System AtrophyChief Executive OfficerSystem AtrophyNeurological DisordersMultiple System Atrophy FactPr NewswireClinical Trials
Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2a '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease - Vimarsana News

Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2a '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease

Published: August 23, 2022

Inhibikase Therapeutics, Inc.

Source: pressreleasepoint.com
Related Topics:
United StatesMiltonh WernerHoehn YahrInhibikase Therapeutics IncAbelson Tyrosine KinaseChief ExecutiveMultiple System AtrophyUs Securities And Exchange CommissionChemical CompoundsClinical MedicineManagement Of Parkinsons DiseaseParkinsons DiseaseProtein Kinase InhibitorTyrosine Kinase